Potentially inappropriate medications in older patients based on Beers criteria: a cross-sectional study of a family medicine practice in Saudi Arabia.
Beers criteria
Saudi Arabia
aged
family medicine
geriatrics
potentially inappropriate medications
Journal
BJGP open
ISSN: 2398-3795
Titre abrégé: BJGP Open
Pays: England
ID NLM: 101713531
Informations de publication
Date de publication:
2020
2020
Historique:
received:
31
07
2019
accepted:
03
10
2019
pubmed:
6
2
2020
medline:
6
2
2020
entrez:
6
2
2020
Statut:
epublish
Résumé
The use of potentially inappropriate medications (PIMs) is an important issue in older patients who are at risk of adverse drug events. To determine the prevalence of PIM use, according to Beers criteria, among an older population (aged ≥65 years) in a large family medicine setting, and to identify the associated risks. A prospective cross-sectional study of patients aged ≥65 years was conducted from June 2017 to June 2018 at the Family and Community Medicine (FCM) clinics of King Saud Medical City (KSMC) in Riyadh, Saudi Arabia. This cross-sectional study included patients aged ≥65 years who were seen at new appointments or followed-up at the FCM clinics of KSMC in Riyadh, Saudi Arabia. Data were collected by extensive face-to-face interviews and from the patients' medical records. A total of 270 older patients aged 72.41 ±6.23 years (mean ±standard deviation [SD]) were included in the present study. The prevalence of PIMs was 60.7% ( This study showed high prevalence of PIMs. Increasing age, female sex, and polypharmacy were found to be significant risk factors for PIM use. The frequency of morbidities was not significantly different among patients with PIMs compared to those without PIMs, except for hypertension and osteoarthritis, which were more common in the PIMs group. The present study reinforces the importance of comprehensive medication management and reviews.
Sections du résumé
BACKGROUND
BACKGROUND
The use of potentially inappropriate medications (PIMs) is an important issue in older patients who are at risk of adverse drug events.
AIM
OBJECTIVE
To determine the prevalence of PIM use, according to Beers criteria, among an older population (aged ≥65 years) in a large family medicine setting, and to identify the associated risks.
DESIGN & SETTING
METHODS
A prospective cross-sectional study of patients aged ≥65 years was conducted from June 2017 to June 2018 at the Family and Community Medicine (FCM) clinics of King Saud Medical City (KSMC) in Riyadh, Saudi Arabia.
METHOD
METHODS
This cross-sectional study included patients aged ≥65 years who were seen at new appointments or followed-up at the FCM clinics of KSMC in Riyadh, Saudi Arabia. Data were collected by extensive face-to-face interviews and from the patients' medical records.
RESULTS
RESULTS
A total of 270 older patients aged 72.41 ±6.23 years (mean ±standard deviation [SD]) were included in the present study. The prevalence of PIMs was 60.7% (
CONCLUSION
CONCLUSIONS
This study showed high prevalence of PIMs. Increasing age, female sex, and polypharmacy were found to be significant risk factors for PIM use. The frequency of morbidities was not significantly different among patients with PIMs compared to those without PIMs, except for hypertension and osteoarthritis, which were more common in the PIMs group. The present study reinforces the importance of comprehensive medication management and reviews.
Identifiants
pubmed: 32019777
pii: bjgpopen20X101009
doi: 10.3399/bjgpopen20X101009
pmc: PMC7330182
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright © 2020, The Authors.
Références
Ann Emerg Med. 2001 Dec;38(6):666-71
pubmed: 11719747
Gerontol Geriatr Med. 2016 Mar 16;2:2333721416637790
pubmed: 28138491
Geriatr Gerontol Int. 2013 Jul;13(3):616-21
pubmed: 23035714
Drugs Real World Outcomes. 2015 Sep;2(3):249-259
pubmed: 27747571
Chin Med J (Engl). 2016 Jan 5;129(1):22-7
pubmed: 26712428
J Clin Pharm Ther. 2015 Feb;40(1):7-13
pubmed: 25271047
Drugs Aging. 2005;22(1):69-82
pubmed: 15663350
Geriatrics (Basel). 2019 May 15;4(2):
pubmed: 31096616
J Nutr Health Aging. 2014 Jan;18(1):87-91
pubmed: 24402395
BMC Geriatr. 2009 Jul 23;9:30
pubmed: 19627577
J Gerontol Nurs. 2005 Sep;31(9):4-11
pubmed: 16190007
Aliment Pharmacol Ther. 2011 Dec;34(11-12):1269-81
pubmed: 21999643
PLoS One. 2014 Apr 10;9(4):e94350
pubmed: 24722537
BMC Fam Pract. 2016 Jul 22;17:93
pubmed: 27449802
J Manag Care Pharm. 2005 Sep;11(7):575-83
pubmed: 16137215
J Am Geriatr Soc. 2015 Nov;63(11):2227-46
pubmed: 26446832
Ann Pharmacother. 2000 Mar;34(3):338-46
pubmed: 10917382
CMAJ Open. 2016 Jun 22;4(2):E346-51
pubmed: 27398383
Clin Interv Aging. 2008;3(2):383-9
pubmed: 18686760
Arch Intern Med. 2005 Jan 10;165(1):68-74
pubmed: 15642877
Int J Clin Pharm. 2012 Aug;34(4):626-32
pubmed: 22692715
Korean J Fam Med. 2016 Nov;37(6):329-333
pubmed: 27900070
J Am Geriatr Soc. 1996 Jul;44(7):751-5
pubmed: 8675920
Int J Emerg Med. 2011 Jun 02;4(1):22
pubmed: 21635734
Int J Clin Pharmacol Ther. 2012 Mar;50(3):185-94
pubmed: 22373831
Saudi J Biol Sci. 2017 Jan;24(1):200-207
pubmed: 28053591
J Hum Hypertens. 2002 Sep;16(9):631-5
pubmed: 12214259
PLoS One. 2014 Feb 05;9(2):e88272
pubmed: 24505459
Cochrane Database Syst Rev. 2012 May 16;(5):CD008165
pubmed: 22592727
Am J Geriatr Pharmacother. 2009 Apr;7(2):84-92
pubmed: 19447361